AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,830.00
-150.00 (-1.88%)
Jun 5, 2025, 3:30 PM KST

AptaBio Therapeutics Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Revenue
3,1063,361323.8748.35
Revenue Growth (YoY)
229.91%937.76%569.80%-
Cost of Revenue
2,8863,087262.811.15
Gross Profit
220.53273.6961.0637.21
Selling, General & Admin
3,7113,8933,3852,788
Research & Development
14,23214,59112,3806,197
Other Operating Expenses
120.85113.05130.0374.48
Operating Expenses
20,45620,98916,9659,544
Operating Income
-20,236-20,715-16,904-9,507
Interest Expense
-2,979-3,401-1,183-4.49
Interest & Investment Income
2,0392,2961,9841,572
Earnings From Equity Investments
-428.22-625.93-4.19-
Currency Exchange Gain (Loss)
-214.79-252.8-29.52-14.43
Other Non Operating Income (Expenses)
-4,666-4,6511,68842.49
EBT Excluding Unusual Items
-26,485-27,350-14,448-7,911
Gain (Loss) on Sale of Investments
69.91-452.59-244.29-2,654
Pretax Income
-26,416-27,803-14,692-10,565
Income Tax Expense
1,5751,575-2,630-
Net Income
-27,991-29,378-12,062-10,565
Preferred Dividends & Other Adjustments
---195.14-
Net Income to Common
-27,991-29,378-11,866-10,565
Shares Outstanding (Basic)
24242222
Shares Outstanding (Diluted)
24242222
Shares Change (YoY)
6.87%5.58%0.05%-
EPS (Basic)
-1161.66-1247.79-532.16-474.00
EPS (Diluted)
-1161.66-1247.79-532.16-474.00
Free Cash Flow
-16,527-12,400-15,440-7,874
Free Cash Flow Per Share
-685.88-526.67-692.42-353.27
Gross Margin
7.10%8.14%18.86%76.95%
Operating Margin
-651.42%-616.35%-5219.25%-19661.23%
Profit Margin
-901.05%-874.09%-3663.98%-21849.26%
Free Cash Flow Margin
-532.01%-368.94%-4767.39%-16284.04%
EBITDA
-19,704-20,184-16,364-9,022
D&A For EBITDA
532.1531.35539.11484.62
EBIT
-20,236-20,715-16,904-9,507
Advertising Expenses
-937.07
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.